Development of calcium alginate beads containing paclitaxel-loaded lipid-core nanocapsules intended for oral administration

T. M. Ciocheta, Aline de Cristo Soares Alves, D. R. Dallemole, R. Cé, Silvia Stanisçuaski Guterres, Adriana Raffin Pohlmann
{"title":"Development of calcium alginate beads containing paclitaxel-loaded lipid-core nanocapsules intended for oral administration","authors":"T. M. Ciocheta, Aline de Cristo Soares Alves, D. R. Dallemole, R. Cé, Silvia Stanisçuaski Guterres, Adriana Raffin Pohlmann","doi":"10.22456/2527-2616.122299","DOIUrl":null,"url":null,"abstract":"We developed a solid formulation of calcium alginate beads containing paclitaxel-loaded lipid-core nanocapsules (PTX-LNC-Bead) intended for oral administration. The PTX-LNC liquid formulation was prepared by interfacial deposition and trapped into calcium alginate beads. These beads were characterized in terms of size, morphology, swelling rate, encapsulation efficiency, and release of PTX and LNC in simulated gastrointestinal fluids. Results showed that the beads were gastro-resistant with low swelling rate and drug release lower than 3.5% at pH 1.2 (2h). At pH 6.8, the beads showed high swelling rate and disintegration after 80 min. Drug release was 60% after 600 min. Particle sizing as a function of time confirmed that LNC were released intact from the beads at pH 6.8 showing that PTX-LNC-Bead is a promising product for PTX oral administration. Our results pave the way for novel formulations intended for drug targeting by the oral route.","PeriodicalId":11314,"journal":{"name":"Drug Analytical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Analytical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22456/2527-2616.122299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We developed a solid formulation of calcium alginate beads containing paclitaxel-loaded lipid-core nanocapsules (PTX-LNC-Bead) intended for oral administration. The PTX-LNC liquid formulation was prepared by interfacial deposition and trapped into calcium alginate beads. These beads were characterized in terms of size, morphology, swelling rate, encapsulation efficiency, and release of PTX and LNC in simulated gastrointestinal fluids. Results showed that the beads were gastro-resistant with low swelling rate and drug release lower than 3.5% at pH 1.2 (2h). At pH 6.8, the beads showed high swelling rate and disintegration after 80 min. Drug release was 60% after 600 min. Particle sizing as a function of time confirmed that LNC were released intact from the beads at pH 6.8 showing that PTX-LNC-Bead is a promising product for PTX oral administration. Our results pave the way for novel formulations intended for drug targeting by the oral route.
含有紫杉醇负载脂核纳米胶囊用于口服的海藻酸钙珠的研制
我们开发了一种含有紫杉醇负载脂核纳米胶囊(PTX-LNC-Bead)的海藻酸钙珠固体制剂,用于口服。采用界面沉积法制备PTX-LNC液体配方,并将其包裹在海藻酸钙微球中。这些微球的大小、形态、溶胀率、包封效率以及PTX和LNC在模拟胃肠道液体中的释放情况都得到了表征。结果表明,在pH 1.2 (2h)下,微球具有胃耐药性,溶胀率低,药物释放量低于3.5%。pH为6.8时,微球在80分钟后溶胀率高,崩解率高。600分钟后药物释放率为60%。粒径随时间的变化证实,pH为6.8时,微球完整地从微球中释放出来,表明PTX-LNC- bead是一种很有前景的PTX口服产品。我们的结果为通过口服途径靶向药物的新型制剂铺平了道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信